June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Retinal Delivery of Bevacizumab: Anti-aggregation Diluent Eye Drops for Ocular Delivery in Rabbits
Author Affiliations & Notes
  • Steven A. Giannos
    Ophthalmology and Visual Sciences, University of Texas Medical Branch , Galveston, Texas, United States
  • Edward R. Kraft
    Ophthalmology and Visual Sciences, University of Texas Medical Branch , Galveston, Texas, United States
  • Jaafar El-Annan
    Ophthalmology and Visual Sciences, University of Texas Medical Branch , Galveston, Texas, United States
  • Mary E. Schmitz-Brown
    Ophthalmology and Visual Sciences, University of Texas Medical Branch , Galveston, Texas, United States
  • Valentina Reffatto
    Ophthalmology and Visual Sciences, University of Texas Medical Branch , Galveston, Texas, United States
  • Elizabeth Urias
    Ophthalmology and Visual Sciences, University of Texas Medical Branch , Galveston, Texas, United States
  • Kevin H. Merkley
    Ophthalmology and Visual Sciences, University of Texas Medical Branch , Galveston, Texas, United States
  • Praveena Gupta
    Ophthalmology and Visual Sciences, University of Texas Medical Branch , Galveston, Texas, United States
  • Footnotes
    Commercial Relationships   Steven Giannos, University of Texas Medical Branch (P); Edward Kraft, University of Texas Medical Branch (P); Jaafar El-Annan, None; Mary Schmitz-Brown, None; Valentina Reffatto, None; Elizabeth Urias, None; Kevin Merkley, None; Praveena Gupta, None
  • Footnotes
    Support  This work was supported by a grant from United Molecule, LLC Dallas, Texas.
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4919. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steven A. Giannos, Edward R. Kraft, Jaafar El-Annan, Mary E. Schmitz-Brown, Valentina Reffatto, Elizabeth Urias, Kevin H. Merkley, Praveena Gupta; Retinal Delivery of Bevacizumab: Anti-aggregation Diluent Eye Drops for Ocular Delivery in Rabbits. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4919.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal injections of anti-VEGF monoclonal antibodies are used to treat wet age-related macular degeneration (AMD) and diabetic retinopathy (DR). An anti-aggregation formula (AAF) enables transscleral permeation of bevacizumab, aflibercept and ranibizumab. This study assessed the in vivo feasibility of delivering bevacizumab to the back of the eye using AAF as the diluent for an eye drop.

Methods : Fourteen, New Zealand F1 rabbits - designated Group 1 (bevacizumab in AAF, 5 mg/ml (0.5%)); Group 2 (bevacizumab in PBS, 5 mg/ml (0.5%)) and Vehicle control (AAF). Materials and methods, for the preparation of AAF and PBS were previously described (Giannos et al, Pharm. Res. 2018). Hyaluronic acid (HA) 0.1% was added to AAF, PBS and AAF vehicle control to aid in mucoadhesion. AAF/HA and PBS/HA compositions were sterile filtered prior to addition of 5 mg/ml bevacizumab. AAF vehicle control was absent bevacizumab. Rabbits received an eye drop of approximately 100 µL in each eye, twice daily for 14.5 days, providing a total of 1 mg/day/eye. Aqueous, vitreous, and retina, samples were collected into aliquots containing pre-weighed AAF composition as an assay diluent. Quantitative ELISA was performed to analyze for, and determine the delivered concentration free bevacizumab.

Results : Bevacizumab in AAF permeated and significantly accumulated in the aqueous, vitreous and retina; 10 times or more than when it was diluted in PBS (Table 1). Bevacizumab in AAF/0.1% hyaluronic acid composition with 5 mg/ml bevacizumab, dosed 2 times a day (a clinically relevant dosing schedule) provided higher tissue concentrations in aqueous (1950%), vitreous (100%) and retina (62%) compared to prior work (Nomoto et al. IOVS 2009), using 5 times higher (25 mg/ml) concentrations dosed with a clinically unacceptable schedule (6 times/day).

Conclusions : When diluted in AAF and administered topically, bevacizumab permeated and accumulated in rabbit aqueous, vitreous and retina significantly higher, than when diluted in PBS under the same conditions. Diseased human (AMD & DR), show VEGF from 0.1 to 1.3 ng/ml in the vitreous. Our topical delivery of bevacizumab represents an achievable 1.3x in stoichiometric ratio of drug to VEGF concentration in vitreous for an untreated AMD or DR patient.

This is a 2020 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×